Cooperation in the Pacific Rim by Jakob Polacsek, World Economic Forum (CC BY-NC-SA 2.0) https://www.flickr.com/photos/worldeconomicforum/48179628441

Digital Trade

Assorted pharmaceuticals by Global Panorama (CC BY-SA 2.0) https://flic.kr/p/obLg76

Canadian Government Officials Confirm TPP Will Raise Pharmaceutical Costs

Critics of trade agreements such as the TPP and the Canada-EU Trade Agreement has emphasized that a key concern is that deals will lead to increased costs for pharmaceutical drugs. At a recent Standing Committee on Health hearing on the development of a national pharmacare program, officials with Health Canada confirmed that they expect prices to increase but remain unsure about how much (hat tip: Blacklock’s Reporter). The exchange came from questions by NDP MP Don Davies:

Mr. Davies: Canada has just signed two trade deals, CETA and the TPP, which have new intellectual property provisions. All the literature and opinions I’ve read indicate that this will delay the introduction of generics to market for some time. I’m seeing estimates of two years as about what it’s going to take. Ms. Hoffman, has the department done some analysis on the likely impact of TPP and CETA, and is it true that those trade deals will likely increase the prices that Canadians pay for pharmaceuticals and add a little bit of mud to that already dirty picture?

May 11, 2016 — 9 comments — News

STOP TPP by Chris West (CC BY 2.0) https://flic.kr/p/qohXkM

The Trouble with the TPP: My Appearance Before the International Trade Committee

Yesterday I appeared alongside Jim Balsillie, former co-CEO of Research in Motion, at the House of Commons Standing Committee on International Trade public consultation on the TPP. There were some interesting exchanges that I will highlight once the transcript is released. My opening remarks are posted below.

Appearance before the House of Commons Standing Committee on International Trade, May 5, 2016

Good morning. My name is Michael Geist. I am a law professor at the University of Ottawa, where I hold the Canada Research Chair in Internet and E-commerce Law. I appear today in a personal capacity representing only my own views.

There is lots to say about the TPP – I have written dozens of articles and posts on the agreement and I am currently working on a book on point – but I have limited time so I’ll focus briefly on four issues.

May 6, 2016 — 3 comments — Committees, News

TPP Vancouver Rally by Leadnow Canada (CC BY-NC 2.0) https://flic.kr/p/GooPJ6

The TPP, IP, and Digital Policy: My CABE Presentation

Earlier this week, I delivered a webinar for the Canadian Association of Business Economics on the implications of the TPP. The talk touched on a wide range of concerns including copyright, privacy, culture, and digital policies. A video of the talk can be found here.

https://player.vimeo.com/video/164490514?byline=0&portrait=0

May 4, 2016 — 12 comments — News

Canadian Officials Admit TPP IP Policy Runs Counter To Preferred National Strategy

Today is World IP Day, which marks the creation of the World Intellectual Property Organization. Canadian policy has long preferred the use of international bodies like WIPO to advance its IP objectives, yet the intellectual property provisions in recently concluded trade deals such as the TPP and CETA run counter to Canadian strategy. That isn’t just the opinion of the many critics of those agreements. It is what government officials told International Trade Minister Chrystia Freeland as part of her briefing materials.

The briefing document on intellectual property and the trade agenda, released under the Access to Information Act, leaves little doubt that trade officials are well aware that the Canadian position on IP in the TPP is inconsistent with our preferred position and that it will lead to IP trade deficits. The document states:

Canada’s preferred strategy is to establish international IP rules through multilateral forums such as the World Intellectual Property Organization (WIPO) and the World Trade Organization (WTO). However, in the context of the Canada-EU Comprehensive Economic Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP), Canada negotiated trade obligations that, while reflective of recent domestic reforms, are beyond those standards set through multilateral forums, and which will likely require amendments to domestic practice, such as in the areas of geographical indications (GIs) and patent protection for pharmaceuticals.

April 26, 2016 — 2 comments — News

Patent by Brook (CC BY-NC-ND 2.0) https://flic.kr/p/3fKqYy

U.S. State Department vs. USTR on Eli Lilly and Canadian Patent Utility Rules

The Eli Lilly claim against Canada for hundreds of millions due to a court decision involving patent utility has attracted considerable attention with fears that the case foreshadows many more corporate lawsuits if the Trans Pacific Partnership becomes a reality. While the Canadian government has raised doubts about the independence of the Canadian Chamber of Commerce intervention in the case, the government must be a bit confused on where the U.S. stands on the issue. Yesterday, the U.S. Trade Representative issued its 2016 report on foreign trade barriers and stated the following on the case:

With respect to pharmaceuticals, the United States continues to have serious concerns about the impact of the patent utility requirements that Canadian courts have adopted.

That is consistent with the Eli Lilly argument, yet last month the U.S. State Department provided its own submission in the case. The U.S. government appears to undermine USTR arguments, seemingly siding with the Canada on the issue. The U.S. submission states each country has the right to determine how it implements the utility requirement, the possibility of revocation of patent rights, and for its patent laws to evolve:

April 1, 2016 — Comments are Disabled — News